Performance of Two Risk-Stratification Models in Hospitalized Patients With Coronavirus Disease

Rong Xu1, Keke Hou2, Kun Zhang1

  • 1Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, Department of Radiology, West China Second University Hospital, Sichuan University, Chengdu, China.

Frontiers in Medicine
|September 14, 2020
PubMed

Insights

The new MuLBSTA score effectively identifies severe COVID-19 patients at risk for intensive care unit (ICU) admission and death. This tool aids early risk stratification for better patient outcomes in coronavirus disease 2019 (COVID-19) cases.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Medical Informatics

Background:

  • Coronavirus disease 2019 (COVID-19) poses challenges due to a lack of rapid risk stratification tools for severe cases.
  • Effective prediction of poor outcomes in COVID-19 patients remains a critical unmet need.

Purpose of the Study:

  • To evaluate the efficacy of the novel Multi-lobular infiltration, hypo-Lymphocytosis, Bacterial coinfection, Smoking history, hyper-Tension and Age (MuLBSTA) Score for predicting severe COVID-19 outcomes.
  • To compare the MuLBSTA score with the Confusion, Urea, Respiratory rate, Blood pressure, Age 65 (CURB65) score in risk stratification.

Main Methods:

  • Retrospective analysis of 117 hospitalized COVID-19 patients.
  • Calculation and comparison of MuLBSTA and CURB65 scores for predicting intensive care unit (ICU) admission and mortality.
  • Receiver operating characteristic (ROC) curve analysis and Kaplan-Meier (K-M) survival analysis.

Main Results:

  • The MuLBSTA score demonstrated high diagnostic efficiency for predicting death (AUC, 0.956) and ICU care (AUC, 0.875).
  • Patients with a MuLBSTA score ≥ 12 were all severe cases, with significantly higher rates of ICU admission and death compared to CURB65.
  • K-M survival analysis confirmed that a MuLBSTA score ≥ 12 is associated with a higher risk of ICU admission (P = 0.001) and death (P = 0.000).

Conclusions:

  • The MuLBSTA score is a valuable tool for the rapid risk stratification of COVID-19 patients upon admission.
  • It effectively screens high-risk individuals who are likely to require ICU care or succumb to the infection.
  • The MuLBSTA score offers superior predictive performance compared to CURB65 for severe COVID-19 outcomes.

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
461
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
1.5K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
856
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
441
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
119
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
149